US U.S. ready to roll out boosters pending FDA, CDC approval - surgeon general
Evidence and equity, not politics, should guide booster shots
As the Biden administration readies a plan for COVID-19 booster shots, we must heed past lessons and ensure the authorization process can run its proper course. The federal government and state and local public health departments are wise to plan for the potential authorization of boosters. But arbitrary timelines are not the answer. Reports indicate that the administration now recognizes its planned Sept. 20 rollout date for boosters to the general public is premature. The FDA's independent Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet on Sept.
WASHINGTON (Reuters) - The United States is ready to roll out COVID-19 vaccine booster shots once the Federal Drugs Administration and the Centers for Disease Control and Prevention approve the plan, Surgeon General Vivek Murthy said on Friday.
"As soon as the FDA and CDC complete their evaluations, we will be ready to move forward accordingly," Murthy told reporters at a White House briefing.
The CDC will invest $2.1 billion to protect patients and healthcare workers from COVID-19 and future infectious diseases, CDC Director Rochelle Walensky said at the briefing.
So far 89% of active U.S. military troops have received at least one COVID-19 vaccine shot, said White House coronavirus response coordinator Jeff Zients.
(Reporting by Lisa Lambert, Ahmed Aboulenein, and Steve Holland; Editing by Chizu Nomiyama)
Booster confusion takes hold as Biden announces expanded eligibility .
"We have the tools to beat Covid if we come together as a country and use the tools we have," Biden said.Biden said his administration will begin to deliver booster shots after the nation’s two leading health agencies endorsed a third dose of the Pfizer-BioNtech vaccine for people 65 and older and those at elevated risk of severe Covid-19. The announcement is the culmination of weeks of debate inside the administration about whether data showed that vaccine efficacy was waning enough to begin to roll out doses to large swathes of the country.